Eli Lilly raised its full-year sales outlook after reporting third-quarter earnings and revenue that beat analyst estimates. Demand for its weight loss drug Zepbound and diabetes treatment Mounjaro grew again.

The company now expects 2026 revenue of $91 billion to $92 billion, up from its previous guidance of $85 billion to $87 billion. Lilly projects full-year adjusted earnings of $35 to $36 per share, compared with its earlier outlook of $35.50 to $36.50 per share. The company said the change reflects $4.57 per share in charges tied to deals made in the quarter, which offset a $4.07 per share increase in underlying profit guidance at the midpoint. Lilly shares rose about 7% on Thursday.

Mounjaro's worldwide revenue rose 65% to $10.72 billion, above the $10.10 billion analysts expected, according to StreetAccount. Zepbound posted $5.35 billion in revenue, up 49% from a year earlier and above the $5.09 billion analysts expected.

Sales of Foundayo, Lilly's new GLP-1 obesity pill approved in the U.S. in April, reached $184 million. That was below analyst forecasts of about $229 million. Lilly CFO Lucas Montarces said U.S. prescriptions for Foundayo and the number of new patients doubled from the previous quarter. He said about 4 in 10 patients starting an oral obesity medicine chose Foundayo. Lilly expects Foundayo to receive U.S. approval for Type 2 diabetes in the fourth quarter.

According to a Lilly earnings presentation, the company held 63% of the U.S. obesity and diabetes drug market in the third quarter, while Novo Nordisk had 36.6%. Internationally, Lilly held 58.4% share.

CEO Dave Ricks told CNBC that he estimates 3% to 10% of eligible patients in the U.S. currently access obesity care, and said the "room for expansion here of this market is dramatic." Lilly also pointed to Medicare's temporary pilot program, which began covering GLP-1s for weight loss in July, and Ricks said he was pleased with early uptake.

Lilly reported U.S. revenue up 34% to $15.1 billion, with volume up 41% and realized prices down 7%, mainly due to Zepbound. Sales outside the U.S. rose 47% to $9.3 billion. The company booked net income of $6.45 billion, or $7.22 per share, for the quarter, compared with $6.21 per share a year earlier. Excluding one-time items, Lilly reported earnings of $7.48 per share.